Search

Your search keyword '"Scott, Sam N."' showing total 33 results
Start Over Author "Scott, Sam N."
33 results on '"Scott, Sam N."'

2. Type I Diabetes and Exercise

Author

Scott, Sam N., Riddell, Michael C., Yardley, Jane E., Poretsky, Leonid, Series Editor, Hackney, Anthony C., editor, and Constantini, Naama W., editor

Published
2020
Full Text
View/download PDF

4. The competitive athlete with type 1 diabetes

Author

Riddell, Michael C., Scott, Sam N., Fournier, Paul A., Colberg, Sheri R., Gallen, Ian W., Moser, Othmar, Stettler, Christoph, Yardley, Jane E., Zaharieva, Dessi P., Adolfsson, Peter, and Bracken, Richard M.

Published
2020
Full Text
View/download PDF

7. Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: Retrospective, observational study over an entire competitive season

Author

van Weenen, Eva, primary, Banholzer, Nicolas, additional, Föll, Simon, additional, Zueger, Thomas, additional, Fontana, Federico Y., additional, Skroce, Kristina, additional, Hayes, Charlotte, additional, Kraus, Mathias, additional, Feuerriegel, Stefan, additional, Lehmann, Vera, additional, Scott, Sam N., additional, Wortmann, Felix, additional, and Stettler, Christoph, additional

Published
2023
Full Text
View/download PDF

9. Development of a Novel Home-Based Exergame With On-Body Feedback: Usability Study

Author

Schättin, Alexandra, primary, Pickles, Jordan, additional, Flagmeier, David, additional, Schärer, Benjamin, additional, Riederer, Yanick, additional, Niedecken, Stephan, additional, Villiger, Stefan, additional, Jurt, Roman, additional, Kind, Nicole, additional, Scott, Sam N, additional, Stettler, Christoph, additional, and Martin-Niedecken, Anna Lisa, additional

Published
2022
Full Text
View/download PDF

18. Glycemic responses to strenuous training in male professional cyclists with type 1 diabetes: a prospective observational study

Author

McCarthy, Olivia, primary, Eckstein, Max L, additional, Scott, Sam N, additional, Fontana, Federico Y, additional, Christiansen, Mark P, additional, Stettler, Christoph, additional, Fisher, Miles, additional, Bode, Bruce, additional, Riddell, Michael C, additional, Hayes, Charlotte, additional, Lagrou, Peter L, additional, Southerland, Phil, additional, Moser, Othmar, additional, and Bracken, Richard M, additional

Published
2020
Full Text
View/download PDF

19. Evaluation of Factors Related to Glycemic Management in Professional Cyclists With Type 1 Diabetes Over a 7-Day Stage Race

Author

Scott, Sam N., primary, Christiansen, Mark P., additional, Fontana, Federico Y., additional, Stettler, Christoph, additional, Bracken, Richard M., additional, Hayes, Charlotte A., additional, Fisher, Miles, additional, Bode, Bruce, additional, Lagrou, Peter H., additional, Southerland, Phil, additional, and Riddell, Michael C., additional

Published
2020
Full Text
View/download PDF

22. A Multidisciplinary Evaluation of a Virtually Supervised Home-Based High-Intensity Interval Training Intervention in People With Type 1 Diabetes

Author

Scott, Sam N., primary, Shepherd, Sam O., additional, Andrews, Rob C., additional, Narendran, Parth, additional, Purewal, Tejpal S., additional, Kinnafick, Florence, additional, Cuthbertson, Daniel J., additional, Atkinson-Goulding, Sandra, additional, Noon, Tom, additional, Wagenmakers, Anton J.M., additional, and Cocks, Matt, additional

Published
2019
Full Text
View/download PDF

23. Home‐hit improves muscle capillarisation and eNOS/NAD(P)Hoxidase protein ratio in obese individuals with elevated cardiovascular disease risk

Author

Scott, Sam N., primary, Shepherd, Sam O., additional, Hopkins, Nicola, additional, Dawson, Ellen A., additional, Strauss, Juliette A., additional, Wright, David J., additional, Cooper, Robert G., additional, Kumar, Pradesh, additional, Wagenmakers, Anton J. M., additional, and Cocks, Matthew, additional

Published
2019
Full Text
View/download PDF

24. 67-LB: Time Spent in Glycaemic Ranges and Carbohydrate Intake during Cycling in Professional Cyclists with Type 1 Diabetes

Author

MCCARTHY, OLIVIA, primary, MOSER, OTHMAR, additional, ECKSTEIN, MAX L., additional, SCOTT, SAM N., additional, RIDDELL, MICHAEL, additional, FISHER, MILES, additional, FONTANA, FEDERICO Y., additional, SKROCE, KRISTINA, additional, FESTA, LUCA, additional, LAGROU, PETER HENDRIK, additional, SOUTHERLAND, PHIL, additional, HAYES, CHARLOTTE A., additional, CHRISTIANSEN, MARK P., additional, BODE, BRUCE W., additional, STETTLER, CHRISTOPH, additional, and BRACKEN, RICHARD M., additional

Published
2019
Full Text
View/download PDF

25. 66-LB: Greater Time Spent in Hypoglycemia during Night Compared with Day during Intensified Training in Professional Cyclists with Type 1 Diabetes—A Prospective Observational Study

Author

MOSER, OTHMAR, primary, ECKSTEIN, MAX L., additional, MCCARTHY, OLIVIA, additional, RIDDELL, MICHAEL, additional, FONTANA, FEDERICO Y., additional, SKROCE, KRISTINA, additional, FESTA, LUCA, additional, SOUTHERLAND, PHIL, additional, CHRISTIANSEN, MARK P., additional, BODE, BRUCE W., additional, STETTLER, CHRISTOPH, additional, SCOTT, SAM N., additional, FISHER, MILES, additional, HAYES, CHARLOTTE A., additional, and BRACKEN, RICHARD M., additional

Published
2019
Full Text
View/download PDF

27. Use and perception of telemedicine in people with type 1 diabetes during the COVID‐19 pandemic—Results of a global survey.

Author

Scott, Sam N., Fontana, Federico Y., Züger, Thomas, Laimer, Markus, and Stettler, Christoph

Subjects
TELEMEDICINE, TYPE 1 diabetes, COVID-19 pandemic
Abstract

Introduction: The COVID‐19 pandemic has forced rapid reconsideration as to the way in which health care is delivered. One potential means to provide care while avoiding unnecessary person‐to‐person contact is to offer remote services (telemedicine). This study aimed to (1) gather real‐time information on the use and perception of telemedicine in people living with type 1 diabetes and (2) assess the challenges, such as restricted access to health care and/or medical supplies. Methods: An anonymous questionnaire was widely distributed between 24 March and 5 May 2020 using an open‐access web‐based platform. Data were analysed descriptively, and results were stratified according to age, sex and HbA1c. Results: There were 7477 survey responses from individuals in 89 countries. Globally, 30% reported that the pandemic had affected their healthcare access due to cancelled physical appointments with their healthcare providers. Thirty‐two per cent reported no fundamental change in their medical follow‐up during this period, with 9% stating that no personal contact was established with their doctors over the duration of the study. Twenty‐eight per cent received remote care through telephone (72%) or video‐calls (28%). Of these, 86% found remote appointments useful and 75% plan to have remote appointments in the future. Glucose control, indicated by HbA1c, was positively associated with positive perception of telemedicine. In males, 45% of respondents with an HbA1c > 9% rated telemedicine not useful compared to those with lower HbA1c, while 20% of females with an HbA1c > 9% rated it not useful (χ2 = 14.2, P =.0016). Conclusion: Remote appointments have largely been perceived as positive in people with type 1 diabetes with the majority (75%) stating that they would consider remote appointments beyond the pandemic. Age and level of education do not appear to influence perception of telemedicine, whereas poor glucose control, particularly in males, seems to negatively affect perception. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. High-Intensity Interval Training Improves Aerobic Capacity Without a Detrimental Decline in Blood Glucose in People With Type 1 Diabetes.

Author

Scott, Sam N, Cocks, Matt, Andrews, Rob C, Narendran, Parth, Purewal, Tejpal S, Cuthbertson, Daniel J, Wagenmakers, Anton J M, and Shepherd, Sam O

Abstract

We investigated whether 6 weeks of high-intensity interval training (HIT) induced improvements in cardiometabolic health markers similar to moderate-intensity continuous training (MICT) in people with type 1 diabetes (T1D), and whether HIT abolished acute reductions in plasma glucose levels observed after MICT sessions.

Published
2019
Full Text
View/download PDF

31. Fasted High-Intensity Interval and Moderate-Intensity Exercise Do Not Lead to Detrimental 24-Hour Blood Glucose Profiles.

Author

Scott, Sam N, Cocks, Matt, Andrews, Rob C, Narendran, Parth, Purewal, Tejpal S, Cuthbertson, Daniel J, Wagenmakers, Anton J M, and Shepherd, Sam O

Abstract

To compare the effect of a bout of high-intensity interval training (HIT) with a bout of moderate-intensity continuous training (MICT) on glucose concentrations over the subsequent 24-hour period.

Published
2019
Full Text
View/download PDF

33. 65-LB: Sweet Performance: Associations of Maximum Physiological Performance and Diabetes in a Group of World Class Road Cyclists with Type 1 Diabetes.

Author

ECKSTEIN, MAX L., MOSER, OTHMAR, MCCARTHY, OLIVIA, SCOTT, SAM N., RIDDELL, MICHAEL, FONTANA, FEDERICO Y., SKROCE, KRISTINA, CHRISTIANSEN, MARK P., FESTA, LUCA, FISHER, MILES, HAYES, CHARLOTTE A., SOUTHERLAND, PHIL, STETTLER, CHRISTOPH, LAGROU SR., PETER HENDRIK, BRACKEN, BRUCE W., and BODE, RICHARD M.

Abstract

Aim: This study investigated whether markers related to type 1 diabetes (T1D) influence cardiopulmonary exercise (CPX) test performance in a group of world class road cyclists with T1D. Methods: Fifteen elite male road cyclists with T1D (age 27±4 years, T1D duration 11±5 years, BMI 21.6±1.5 kg·min-2, HbA1c 6.8±0.6%) performed a ramped (10 W per min) CPX test to exhaustion. Adjusted stepwise linear regression analysis was performed to investigate relationships between markers of T1D control and absolute maximum markers of performance, maximum oxygen consumption (V O2max), maximum power output (Pmax) and maximum heart rate (HRmax). Associations between submaximal CPX parameters and V O2max,Pmax and HRmax were also investigated. Results: Starting-CPX blood glucose (BG), post-CPX BG, ΔBG, T1D duration, HbA1c and BMI were not associated with V O2max (r2=0.51, P=0.32) and Pmax (r2=0.48, P=0.37) during CPX testing. However, HRmax was associated with T1D duration (r2=0.31, P=0.03). CO2 expiration at the lactate turn point 2 (V CO2LTP2) and power at the heart rate turn point (PHRTP) were associated with V O2max (r2=0.87, P<0.0001). These results were also associated when adjusted for T1D parameters (r2=0.95, p=0.002). Pmax was solely associated with V O2HRTP (r2=0.71, P<0.0001). Also, this association remained significant when adjusted for T1D parameters (r2=0.86, P=0.03).HRmax was associated with ventilation at the LTP2 (VELTP2), LactateLTP1, VCO2LTP2 and PLTP2 (r2=0.91, P=0.002). When this result was adjusted for T1D parameters the association was significant (r2=0.93, P=0.05). Conclusion: This is the first dataset presenting CPX data from a world class cycle team with T1D. The study shows that not all markers of maximum physiological performance are influenced by T1D, solely HRmax by T1D duration. Yet, maximum performance is dependent on several submaximal cardiopulmonary markers of performance. Disclosure: M.L. Eckstein: Research Support; Self; Novo Nordisk A/S. O. Moser: Research Support; Self; Abbott, Dexcom, Inc., Novo Nordisk A/S. O. McCarthy: None. S.N. Scott: None. M. Riddell: Advisory Panel; Self; Xeris Pharmaceuticals, Inc. Consultant; Self; Lilly Diabetes. Research Support; Self; Dexcom, Inc., Insulet Corporation, Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Medtronic MiniMed, Inc., OmniPod. Stock/Shareholder; Self; Zucara Therapeutics Inc. F.Y. Fontana: None. K. Skroce: None. M.P. Christiansen: Research Support; Self; Abbott, Biolinq, Dexcom, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic MiniMed, Inc., Novo Nordisk A/S, Sanofi-Aventis, Xeris Pharmaceuticals, Inc. L. Festa: None. M. Fisher: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Mylan, NAPP Pharmaceuticals Limited, Novo Nordisk A/S. Speaker's Bureau; Self; Eli Lilly and Company, Sanofi. C.A. Hayes: Other Relationship; Self; Novo Nordisk A/S. P. Southerland: Other Relationship; Self; Novo Nordisk Inc. C. Stettler: None. P.H. Lagrou: None. B.W. Bode: Consultant; Self; ADOCIA, Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; Becton, Dickinson and Company, Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Eyenuk Inc., Insulet Corporation, National Institutes of Health, Novo Nordisk Inc., Sanofi Research & Development, Senseonics, Xeris Pharmaceuticals, Inc. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi US, Senseonics. Stock/Shareholder; Self; AgaMatrix, Glytec, LLC. R.M. Bracken: None. Funding: Novo Nordisk A/S [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results